Professor Tim Meyer
Telephone:
Email:
Location:
- University College Hospital
GMC/GDC number:
3442074
Professional background
Tim Meyer is professor of experimental cancer medicine and consultant in medical oncology. He obtained his medical degree from UCL and undertook postgraduate training in London.
He was awarded a PhD for work conducted in Prof Ian Hart’s Lab at the ICRF and was appointed to his current post in 2002.
Specialties
Research interests
- Neuroendocrine cancer
- Hepatocellular cancer drug development
Publications
Walenkamp A, Crespo G, Maya FF, Fossmark R, Igaz P, Rinke A, Tamagno G, Vitale G, Öberg K, Meyer T. Hallmarks of gastrointestinal neuroendocrine tumours: implications for treatment. Endocr Relat Cancer. 2014 Dec;21(6):R445-R460.
Meyer T, Wendi Q, Caplin ME, Armstrong G, Lao-Sirieix S-H, Hardy R, Valle JW, Talbot DC, Cunningham D, Reed N, Shaw A, Navalkissoor S, Luong T-V, Corrie PG. Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. Eu J Cancer 2014; 50, 902– 911
Francis JM, et al Somatic mutation of CDKN1B in small intestine neuroendocrine tumors, Nat Genet. 2013 Dec;45(12):1483-6
Kadalayil L, Benini R, Pallan L, O’Beirne J, Marelli L, Yu D, Hackshaw A, Fox R, Johnson P, Burroughs AK, Palmer DH, Meyer T. A simple prognostic scoring system for patients receiving transarterial-embolisation for hepatocellular cancer. Ann Oncol 2013 Oct;24(10):2565-70
Khan MS, Luong TV, Watkins J, Toumpanakis C, Caplin ME, Meyer T A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms. Br J Cancer. 2013 Mar 14;108(9):1838-45
Meyer T, Roughton M, Yu D, Davies N, Williams E, Pereira SP, Hochhauser D, O'Beirne J, Patch D, Burroughs A K. A randomized phase II/III trial of three weekly cisplatin based transarterial chemoembolization versus embolization alone for hepatocellular cancer. Br J Cancer 2013 108(6):1252-9
Khan MS, Kirkwood A, Tsigani T, Garcia-Hernandez J, Hartley JA, Caplin ME, Meyer T. Circulating Tumor Cells As Prognostic Markers in Neuroendocrine Tumors. J Clin Oncol 2013; 31:365-372
Gillmore R, Stuart S, Kirkwood A, Hameeduddin A, Woodward N, Burroughs AK, Meyer T, EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolisation. J Hepatol 2011; 55 (6):1309-1316
Khan MS, Tsigani T, Rashid M, Rabouhans JS, Yu D, Luong TV, Caplin ME, Meyer T, Circulating Tumour Cells and EpCAM Expression in Neuroendocrine Tumours. Clin Canc Res 2011; 17(2):337-45